French firms call for action on regulatory shortcomings ahead of presidential election
This article was originally published in SRA
Executive Summary
In the run-up to the French presidential elections next month, a group of domestic pharmaceutical companies has issued a "white paper" drawing the candidates' attention to the complex set of procedures that it says are hindering new drugs' access to the market1.